Matthew T. Wiley

Companies

• Definium TherapeuticsChief Commercial Officer Mar 18, 2025 to now¹
• BioXcel Therapeutics, Inc.CHIEF COMMERCIAL OFFICER Jan 19, 2022 to Oct 3, 2024²
• Yarrow Bioscience, Inc.Chief Commercial Officer Mar 11, 2020 to Jul 2, 2021³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• DTDefinium Therapeutics DFTX359,036 shares⁴$12.3M at $34.31Sep 25, 2026
• BTBioXcel Therapeutics, Inc. BTAIQ19,011 shares⁵$570 at $0.03Oct 3, 2024

As of each latest filing. The line shows shares held over time.

Recent filings

• Sep 25, 2026Sold 3,097 shares at $36.57 of Definium Therapeutics⁴
• Sep 14, 2026Granted 125,000 shares of Definium Therapeutics⁶
• Aug 12, 2026Granted 62,500 shares of Definium Therapeutics⁷
• Jun 25, 2026Sold 2,867 shares at $45.03 of Definium Therapeutics⁸
• Jun 22, 2026Granted 62,500 shares of Definium Therapeutics⁹
• Feb 3, 2026Granted 115,000 shares of Definium Therapeutics¹⁰
• Oct 3, 2024Sold 6,272 shares at $0.55 of BioXcel Therapeutics, Inc.⁵
• Sep 17, 2024Granted 21,250 shares of BioXcel Therapeutics, Inc.⁵
• Sep 16, 2024Sold 215 shares at $0.69 of BioXcel Therapeutics, Inc.¹¹
• Sep 15, 2024Exercised options 750 shares of BioXcel Therapeutics, Inc.¹¹
• Jun 17, 2024Sold 244 shares at $1.26 of BioXcel Therapeutics, Inc.¹²
• Jun 15, 2024Exercised options 750 shares of BioXcel Therapeutics, Inc.¹²
• Apr 4, 2024Sold 1,008 shares at $2.64 of BioXcel Therapeutics, Inc.¹³
• Mar 15, 2024Exercised options 3,000 shares of BioXcel Therapeutics, Inc.¹³